Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 6, 2007, Pages 902-908

  Yee, David S ^a   Narula, Navneet ^a   Ramzy, Ibrahim ^a   Boker, John ^a   Ahlering, Thomas E ^a   Skarecky, Douglas W ^a   Ornstein, David K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 2;

APOPTOSIS; ARTICLE; BASAL CELL; CANCER GRADING; CANCER STAGING; CELL FUNCTION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANNEXIN A2; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250155667     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Liu JW, Shen JJ, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene. 2003;22:1475-1485.
2. Klee CB. Ca2+-dependent phospholipids- (and membrane-) binding proteins. Biochemistry. 1988;27:6645-6653.
3. Smith PD, Moss SE. Structural evolution of the annexin supergene family. Trends Genet. 1994;10:241-246.
4. Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci. 1994;15:71-76.
5. McKanna JA. Lipocortin 1 in apoptosis: mammary regression. Anat Rec. 1995;242:1-10.
6. Rothhut B. Participation of annexins in protein phosphorylation. Cell Mol Life Sci. 1997;53:522-526.
7. Oliferenko S, Paiha K, Harber T, et al. Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol. 2005;146:843-854.
8. Lee DB, Jamgotchian N, Allen SG, et al. Annexin A2 heterotetramer: role in tight junction assembly. Am J Physiol. 2004;287:481-491.
9. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
10. Chetcutti A, Margan SH, Russell P, et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 2000;61:6331-6334.
11. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol. 2003;162:255-261.
12. Smitherman AB, Mohler JL, Maygarden SJ, Ornstein DK. Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J Urol. 2004;171:916-920.
13. Kang JS, Calvo BS, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK. Dysregulation of annexin I protein expression in bigh-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res. 2002;8:117-123.
14. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000;21:2235-2242.
15. Paweletz CP, Ornstein DK, Roth M, et al. Loss of annexin I correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000;60:6293-6297.
16. Hedrick L, Epstein JL. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13:389-396.
17. Wojno KJ, Epstein JL. The utility of basal cell specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol. 1995;19:251-260.
18. Parsons JK, Gage WR, Nelson WC, et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619-624.
19. Banerjee AG, Liu J, Yuan Y, et al. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer. 2003;2:34.
20. Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell cancer cell line. Br J Cancer. 1992;65:498-502.
21. Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin it in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis. 1993;14:2575-2579.
22. Emoto K, Sawada H, Yamada Y, et al. Annexin II over expression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339-1345.
23. Zimmerman U, Woenckhaus C, Pietschmann S, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch. 2004;445:368-374.
24. Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA. Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 1992;52:6871-6876.
25. Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004;53:993-1000.
26. Paciucci R, Tora M, Diaz VM, Real FX. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene. 1998;16:625-633.
27. Aguilar S, Corominas JM, Malats N, et al. Tissue plasminogen activator in murine exocrine pancreas cancer. Am J Pathol. 2004;165:1129-1139.
28. Mai J, Waisman DM, Sloane BR. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochem Biophys Acta. 2000;1477:215-230.